Printer Friendly

ISIS ANNOUNCES MANUFACTURING COLLABORATION WITH MILLIPORE

    ISIS ANNOUNCES MANUFACTURING COLLABORATION WITH MILLIPORE
    CARLSBAD, Calif., Nov. 21 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP) reported today that it has entered into a collaboration with Millipore Corporation (NYSE: MIL) regarding the manufacture of antisense drugs using Millipore's chemicals and synthesis and separation systems.  Terms of the agreement were not disclosed.
    Millipore Corporation is a multinational corporation that specializes in separations technology.  Its products and services are widely used in the pharmaceutical and biotechnology industries for research, scale-up and manufacturing.
    Daniel Kisner, M.D., executive vice president of Isis said, "The Millipore collaboration will provide additional resources to Isis in connection with its manufacturing scale-up, and should complement manufacturing scale-up efforts and resources already in place through Isis' relationship with Ciba-Geigy and other collaborators.  In addition, this agreement will support our in-house manufacturing programs."
    The agreement allows Isis and Millipore to enter into similar arrangements with other companies.
    Millipore Corporation, located in Bedford, Mass., is engaged in the development, manufacture and sale of products used for the analysis and purification of fluids utilizing separations technology.
    Isis Pharmaceuticals, Inc. based in Northern San Diego County is engaged in the research and development of a new class of pharmaceutical products based on antisense technology.
    -0-              11/21/91 R
    /CONTACT:  B. Lynne Parshall of Cooley Godward Castro Huddleson & Tatum, 415-494-7622, or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, both for Isis Pharmaceuticals/
    (ISIP) CO:  Isis Pharmaceuticals, Inc. ST:  California IN:  MTC SU: JT-TS -- NY015R -- 5970 11/21/91 14:08 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 21, 1991
Words:250
Previous Article:A BLUEPRINT FOR WASHINGTON: UNIVERSAL STATEWIDE HEALTH INSURANCE
Next Article:WASHINGTON ADOPTS TOUGH OIL SPILL RESPONSE REGULATIONS
Topics:


Related Articles
ISIS ANNOUNCES MANUFACTURING COLLABORATION WITH MILLIPORE
HUMAN GENOME SCIENCES AND ISIS PHARMACEUTICALS FORM ANTISENSE COLLABORATION
ISIS PHARMACEUTICALS AND CIBA ANNOUNCE EXTENSION OF RESEARCH COLLABORATION
ISIS AND BOEHRINGER INGELHEIM SIGN DEFINITIVE AGREEMENT TO FORM CELL ADHESION COLLABORATION; ISIS RECEIVES $28.5 MILLION EQUITY INVESTMENT
ISIS AND CIBA SIGN LETTER OF INTENT TO BROADEN ANTISENSE COLLABORATION AND DEVELOP A SECOND CANCER COMPOUND; CIBA WILL PURCHASE $7 MILLION OF SHARES...
Isis and Merck Establish Research Collaboration for Hepatitis C
Isis Pharmaceuticals' Genetrove division and the R.W. Johnson Pharmaceutical Research Institute initiate antisense target validation program.
Isis and Merck extend Hepatitis C research collaboration.
Isis Pharmaceuticals Reports Third Quarter 2001 Highlights and Financial Results.
Amgen and Isis Pharmaceuticals to collaborate on antisense rugs.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters